Key Points
- CEO August Troendle sold 15,151 shares on Nov. 28 for about $8.99 million (avg $593.46), trimming his position by 2.19% to 675,728 shares worth roughly $401 million.
- Medpace recently beat quarterly estimates with $3.86 EPS (vs. $3.50 est.) and revenue of $659.9M (+23.7% YoY), and set FY2025 guidance of $14.60–14.86 EPS.
- The stock trades at about a 41x P/E with a market cap of $16.56B, yet analysts have a consensus "Hold" rating and an average target of $487.18, below the current share price.
Medpace Holdings, Inc. (NASDAQ:MEDP - Get Free Report) CEO August Troendle sold 15,151 shares of Medpace stock in a transaction on Friday, November 28th. The stock was sold at an average price of $593.46, for a total transaction of $8,991,512.46. Following the completion of the sale, the chief executive officer owned 675,728 shares of the company's stock, valued at approximately $401,017,538.88. This trade represents a 2.19% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink.
Medpace Price Performance
NASDAQ MEDP opened at $587.98 on Tuesday. The company has a market capitalization of $16.56 billion, a price-to-earnings ratio of 41.12, a price-to-earnings-growth ratio of 2.67 and a beta of 1.42. Medpace Holdings, Inc. has a 12 month low of $250.05 and a 12 month high of $626.26. The company's fifty day moving average price is $562.40 and its two-hundred day moving average price is $447.50.
Medpace (NASDAQ:MEDP - Get Free Report) last released its earnings results on Wednesday, October 22nd. The company reported $3.86 earnings per share for the quarter, topping the consensus estimate of $3.50 by $0.36. The company had revenue of $659.90 million during the quarter, compared to the consensus estimate of $640.49 million. Medpace had a net margin of 18.36% and a return on equity of 91.88%. The company's revenue was up 23.7% on a year-over-year basis. During the same quarter in the previous year, the firm earned $3.01 EPS. Medpace has set its FY 2025 guidance at 14.600-14.860 EPS. As a group, analysts anticipate that Medpace Holdings, Inc. will post 12.29 EPS for the current year.
Wall Street Analysts Forecast Growth
Several analysts have issued reports on the company. Rothschild Redb cut Medpace from a "strong-buy" rating to a "hold" rating in a research note on Wednesday, September 3rd. Robert W. Baird set a $613.00 price target on Medpace in a report on Friday, October 24th. Mizuho raised their price objective on Medpace from $575.00 to $655.00 and gave the stock an "outperform" rating in a research note on Friday, October 24th. Zacks Research raised shares of Medpace from a "hold" rating to a "strong-buy" rating in a report on Monday, October 27th. Finally, Truist Financial set a $555.00 target price on shares of Medpace in a report on Monday, October 27th. One equities research analyst has rated the stock with a Strong Buy rating, two have assigned a Buy rating, ten have given a Hold rating and four have given a Sell rating to the company. According to data from MarketBeat.com, Medpace has a consensus rating of "Hold" and an average target price of $487.18.
Read Our Latest Stock Analysis on MEDP
Institutional Inflows and Outflows
A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Quent Capital LLC acquired a new stake in Medpace in the third quarter worth $25,000. Optiver Holding B.V. bought a new position in shares of Medpace during the third quarter worth about $27,000. Quarry LP acquired a new stake in shares of Medpace in the 3rd quarter worth about $35,000. Root Financial Partners LLC bought a new stake in Medpace in the 3rd quarter valued at about $38,000. Finally, Geneos Wealth Management Inc. boosted its stake in Medpace by 64.9% during the 1st quarter. Geneos Wealth Management Inc. now owns 94 shares of the company's stock valued at $29,000 after purchasing an additional 37 shares during the period. Institutional investors and hedge funds own 77.98% of the company's stock.
Medpace Company Profile
(
Get Free Report)
Medpace Holdings, Inc engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. Its services include medical department, clinical trial management, data-driven feasibility, study-start-up, clinical monitoring, regulatory affairs, patient recruitment and retention, medical writing, biometrics and data sciences, pharmacovigilance, core laboratory, laboratories, clinics, and quality assurance.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
